«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《现代肿瘤医学》[ISSN:1672-4992/CN:61-1415/R]

期数:

2021年13期

页码:

2261-2265

栏目:

论著（头颈肿瘤）

出版日期:

2021-05-31

文章信息/Info

Title:

Efficacy of stereotactic radiotherapy combined with temozolomide in the treatment of recurrent glioma

作者:

卫润斐¹; 梁洪磊¹; 曹付强²; 孙 鹏¹; 张俊虎¹; 罗文凯¹

1.安阳市人民医院，河南 安阳 455000；2.解放军第988医院，河南 郑州 313000

Author(s):

WEI Runfei¹; LIANG Honglei¹; CAO Fuqiang²; SUN Peng¹; ZHANG Junhu¹; LUO Wenkai¹

1.Anyang People's Hospital,Henan Anyang 455000,China;2.the 988 Hospital of the People's Liberation Army,Henan Zhengzhou 313000,China.

关键词:

立体定向放射治疗; 替莫唑胺; 复发性脑胶质瘤; 疗效

Keywords:

stereotactic radiotherapy; temozolomide; recurrent glioma; curative effect

分类号:

R739.41

DOI:

10.3969/j.issn.1672-4992.2021.13.012

文献标识码:

A

摘要:

目的：探究立体定向放射治疗联合替莫唑胺治疗复发性脑胶质瘤的临床疗效。方法：纳入2013年01月至2016年03月我院肿瘤科收治的43例复发性脑胶质瘤患者临床资料，所有入组患者均符合脑胶质瘤诊断标准，复发后经磁共振成像（MRI）影像学检查均诊断为原发肿瘤体积增大或出现新发肿瘤病灶；根据随机法将所有入组患者进行分组，对照组20例，行单纯立体定向放射治疗(SRT)；观察组23例，行SRT＋替莫唑胺治疗(TMZ)。将所得数据录入SPSS 17.0统计软件进行分析，观察对比两组患者近期临床疗效、生活质量改善情况及治疗后出现不良反应的发生率，采用Kaplan-Meier法分析两组患者2年内累积生存情况，观察组间差异是否具有统计学意义。α=0.05为检验标准。结果：观察组患者近期临床疗效整体优于对照组，有效率及局部控制率均显著高于对照组（P＜0.05）。观察组患者治疗后生活质量改善情况高于对照组（95.65％ vs 80.00％）。观察组患者的中位生存期为12个月（95%CI：7.802~12.963），对照组患者的中位生存期为9个月（95%CI：5.019~9.689），两组中位生存期组间差异有统计学意义（P＜0.05）。两组患者治疗后不良反应的总发生率无显著差异（40.00％ vs 43.48％，P＞0.05）。结论：立体定向放射治疗联合替莫唑胺治疗复发性脑胶质瘤疗效显著、安全，对提高患者生存率有积极影响。

Abstract:

Objective:To explore the clinical effect of stereotactic radiotherapy combined with temozolomide in the treatment of recurrent glioma.Methods:The clinical data of 43 patients with recurrent glioma admitted to the oncology department of our hospital from January 2013 to March 2016 were included.All the enrolled patients met the diagnostic criteria for glioma.After recurrence,all the patients were diagnosed with increased primary tumor volume or new tumor lesions by magnetic resonance imaging (MRI) examination.According to the randomized method,all patients were divided into groups.The control group received 20 cases of stereotactic radiotherapy (SRT).In the observation group,23 patients were treated with SRT+temozolomide (TMZ).The data were input into SPSS 17.0 statistical software for analysis,and the short-term clinical efficacy,quality of life improvement and incidence of adverse reactions after treatment were observed and compared between the two groups.Kaplan-Meier method was used to analyze the cumulative survival of patients in the two groups within 2 years,and to observe whether the differences between the groups were statistically significant.α=0.05 was the test standard.Results:The short-term clinical efficacy of the observation group was better than that of the control group,and the effective rate and local control rate were significantly higher than those of the control group (P＜0.05).The improvement of quality of life in the observation group was higher than that in the control group (95.65% vs 80.00%).The median survival time of patients in the observation group was 12 months (95%CI:7.802~12.963),and that of patients in the control group was 9 months (95%CI:5.019~9.689),showing statistically significant differences between the two groups (P＜0.05).There was no significant difference in the total incidence of adverse reactions after treatment between the two groups (40.00% vs 43.48%,P＞0.05).Conclusion:Stereotactic radiotherapy combined with temozolomide in the treatment of recurrent glioma is effective and safe,and has a positive effect on the survival rate of patients.

参考文献/References

［1］王镔,赵刚.脑胶质瘤免疫治疗的进展与展望［J］.中国微侵袭神经外科杂志,2018,23(11):523-526. WANG B,ZHAO G.Progress and outlook of immunotherapy for glioma［J］.Chinese Journal of Microinvasive Neurosurgery,2018,23(11):523-526.
［2］张维波,邹胜,黄怀忠,等.不同级别脑胶质瘤手术预后的影响因素分析［J］.现代仪器与医疗,2018,24(06):63-65. ZHANG WB,ZOU S,HUANG HZ,et al.Analysis of influencing factors for surgical prognosis of glioma of different grades［J］.Modern Instruments and Medicine,2018,24(06):63-65.
［3］马成鑫,冯睿,吴劲松.脑胶质瘤相关性癫的发病机制、分类及手术方案选择［J］.中国临床神经科学,2017,25(01):105-111. MA CX,FENG R,WU JS.Pathogenesis,classification and surgical options of epilepsy associated with glioma［J］.Chinese Journal of Clinical Neuroscience,2017,25(01):105-111.
［4］金玮,许修,王龙辰,等.立体定向放疗服务评价体系指标的设计［J］.中国医疗设备,2018,33(09):144-146,157. JIN W,XU X,WANG LC,et al.Design of indexes of stereotactic radiotherapy service evaluation system［J］.Chinese Medical Equipment,2018,33(09):144-146,157.
［5］徐骏.替莫唑胺联合放射治疗复发性恶性脑胶质瘤的临床疗效分析［J］.药品评价,2018,15(23):24-26. XU J.Clinical efficacy analysis of temozolomide combined with radiotherapy for recurrent malignant glioma［J］.Drug Evaluation,2018,15(23):24-26.
［6］廖明朗,文宠佩,林志东.脑胶质瘤的MRI诊断及鉴别诊断［J］.中国老年学杂志,2018,38(20):4901-4903. LIAO ML,WEN CP,LIN ZD.MRI diagnosis and differential diagnosis of glioma［J］.Chinese Journal of Gerontology,2018,38(20):4901-4903.
［7］李论,戴金龙,胡硕,等.磁共振弥散张量成像在脑胶质瘤诊断中应用价值研究［J］.创伤与急危重病医学,2018,6(06):422. LI L,DAI JL,HU S,et al.Application value of magnetic resonance diffusion tensor imaging in the diagnosis of glioma［J］.Journal of Trauma and Critical Care Medicine,2018,6(06):422.
［8］杨志炜,郭天,谢海滨,等.影像组学在脑胶质瘤分级中的应用研究［J］.磁共振成像,2018,9(06):439-445. YANG ZW,GUO T,XIE HB,et al.Application of imaging histology in glioma grading［J］.Magnetic Resonance Imaging,2018,9(06):439-445.
［9］杨丽,张钦红,王兰,等.恶性脑胶质瘤术后应用替莫唑胺治疗的疗效分析［J］.肿瘤药学,2018,8(03):371-373,399. YANG L,ZHANG QH,WANG L,et al.Efficacy analysis of temozolomide in the treatment of malignant glioma after surgery［J］.Cancer Pharmacology,2018,8(03):371-373,399.
［10］马明,牛婷婷,王兵,等.替莫唑胺联合立体定向放射治疗脑转移瘤临床疗效观察［J］.临床军医杂志,2018,46(07):798-799,802. MA M,NIU TT,WANG B,et al.Clinical efficacy of temozolomide combined with stereotactic radiotherapy for brain metastatic tumor［J］.Journal of Clinical Military Medicine,2018,46(07):798-799,802.
［11］陈鹏宇.细胞因子诱导的杀伤细胞免疫疗法联合替莫唑胺治疗恶性脑胶质瘤的疗效［J］.广西医学,2018,40(11):1196-1199. CHEN PY.Efficacy of cytokine induced killer cell immunotherapy combined with temozolomide in the treatment of malignant glioma［J］.Guangxi Med,2018,40(11):1196-1199.
［12］张雷,刘一博,刘继才,等.评价替莫唑胺对脑胶质瘤治疗敏感性的新方法［J］.中国癌症杂志,2018,28(09):657-664. ZHANG L,LIU YB,LIU JC,et al.A new method to evaluate the sensitivity of temozolomide to glioma treatment［J］.Chinese Journal of Cancer,2018,28(09):657-664.
［13］谢才军,张志强,谭齐家,等.替莫唑胺每周交替方案治疗脑转移瘤的临床效果及对生存期的影响［J］.实用医学杂志,2018,34(13):2224-2227. XIE CJ,ZHANG ZQ,TAN QJ,et al.Clinical effect and effect on survival of patients with brain metastatic tumor treated with temozolomide weekly alternating regimen［J］.Journal of Practical Medicine,2018,34(13):2224-2227.
［14］张永森,杨利敏,杨卫泷,等.替莫唑胺对人脑胶质瘤细胞U251增殖、凋亡的影响及其机制探讨［J］.山东医药,2017,57(47):17-19. ZHANG YS,YANG LM,YANG WL,et al.Effects of temozolomide on proliferation and apoptosis of human glioma cells U251 and its mechanism［J］.Shandong Med,2017,57(47):17-19.
［15］WHITEHEAD CA,NGUYEN HPT,MOROKOFF AP.Inhibition of radiation and temozolomide-induced invadopodia activity in glioma cells using FDA-approved drugs［J］.Translational Oncology,2018,11(6):124-128.

备注/Memo

备注/Memo:

河南省卫生和计划生育委员会基金项目（编号：20170126314）

常用功能

更新日期/Last Update: 2021-05-31